Neurocrine Biosciences Inc vs Tripadvisor Inc Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B). The key difference: Neurocrine Biosciences Inc is far larger — about 10.4× Tripadvisor Inc Common Stock's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| NBIX | TRIP | |
|---|---|---|
Market Cap | $17.40B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $19.14 |
52-Week Low | $123.10 | $9.24 |
Enterprise Value | $16.49B | $1.80B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →